Dario A. Paggiarino - Feb 9, 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2022
Transactions value $
-$17,434
Form type
4
Date filed
2/11/2022, 03:39 PM
Previous filing
Jun 23, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4.97K +39.43% $0.00 17.6K Feb 9, 2022 Direct
transaction EYPT Common Stock Tax liability -$17.4K -1.72K -9.8% $10.13 15.8K Feb 9, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +17.5K $0.00 17.5K Feb 9, 2022 Common Stock 17.5K $0.00 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -4.97K -33.33% $0.00 9.93K Feb 9, 2022 Common Stock 4.97K $0.00 Direct F3
transaction EYPT Stock Option (Right to Buy) Award $0 +70K $0.00 70K Feb 9, 2022 Common Stock 70K $10.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F3 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F4 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.